Frovatriptan is Effective and Well Tolerated in Korean Migraineurs: A Double-Blind, Randomized, Placebo-Controlled Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Moon, Heui-Soo | - |
dc.contributor.author | Chu, Min Kyung | - |
dc.contributor.author | Park, Jeong Wook | - |
dc.contributor.author | Oh, Kyungmi | - |
dc.contributor.author | Chung, Jae Myun | - |
dc.contributor.author | Cho, Yong Jin | - |
dc.contributor.author | Kim, Eung Gyu | - |
dc.contributor.author | Do, Jin Kuk | - |
dc.contributor.author | Jung, Hyong Gi | - |
dc.contributor.author | Kwon, Sun Uck | - |
dc.date.accessioned | 2021-09-08T04:40:26Z | - |
dc.date.available | 2021-09-08T04:40:26Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-03 | - |
dc.identifier.issn | 1738-6586 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/116843 | - |
dc.description.abstract | Background and Purpose Frovatriptan is a selective 5-HTIB/ID agonist with a long duration of action and a low incidence of side effects. Although several placebo-controlled trials have documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has not previously been studied in Asian including Korean patients. Methods In this double-blind multicenter trial, 229 patients with migraine were randomized to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine. The primary outcome was the 2-hour headache response rate. Results Frovatriptan significantly increased the 2-hour headache response rate compared with placebo (52.9% vs. 34.0%, p=0.004). The headache response rates at 4, 6, and 12 hours were significantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2 hours (19.0% vs. 5.7%, p=0.004), 4 hours (40.7% vs. 23.0%, p=0.006), and 6 hours (56.1% vs. 34.0%, p=0.002). The median time to a headache response was significantly shorter in the frovatriptan group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications was more common in the placebo group (p=0.005). Chest tightness associated with triptan was infrequent (2.5%), mild, and transient. Conclusions These results demonstrate that 2.5-mg frovatriptan is effective and well tolerated in Korean migraineurs for acute treatment of migraine attacks. J Clin Neurol 2010;6:27-32 | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN NEUROLOGICAL ASSOC | - |
dc.subject | EFFICACY | - |
dc.subject | ZOLMITRIPTAN | - |
dc.subject | TRIPTANS | - |
dc.subject | JAPANESE | - |
dc.subject | PHARMACOKINETICS | - |
dc.subject | SEROTONIN | - |
dc.subject | TABLETS | - |
dc.subject | SAFETY | - |
dc.title | Frovatriptan is Effective and Well Tolerated in Korean Migraineurs: A Double-Blind, Randomized, Placebo-Controlled Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Kyungmi | - |
dc.identifier.doi | 10.3988/jcn.2010.6.1.27 | - |
dc.identifier.scopusid | 2-s2.0-78651488665 | - |
dc.identifier.wosid | 000276088800004 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL NEUROLOGY, v.6, no.1, pp.27 - 32 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL NEUROLOGY | - |
dc.citation.title | JOURNAL OF CLINICAL NEUROLOGY | - |
dc.citation.volume | 6 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 27 | - |
dc.citation.endPage | 32 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001435353 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | ZOLMITRIPTAN | - |
dc.subject.keywordPlus | TRIPTANS | - |
dc.subject.keywordPlus | JAPANESE | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | SEROTONIN | - |
dc.subject.keywordPlus | TABLETS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | migraine | - |
dc.subject.keywordAuthor | frovatriptan | - |
dc.subject.keywordAuthor | Korean | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.